Cost-benefit analysis of the introduction of mass vaccination against Hepatitis B in Italy

1993 ◽  
Keyword(s):  
Hepatitis B ◽  
Cost Benefit Analysis ◽  
Cost Benefit ◽  
Mass Vaccination ◽  
Benefit Analysis

COST-BENEFIT ANALYSIS OF HEPATITIS-B VACCINATION

The Lancet ◽  
1987 ◽  
Vol 330 (8556) ◽  
pp. 441-443 ◽  
Author(s):  
D. Lahaye ◽  
C. Baleux ◽  
P. Strauss ◽  
W.Van Ganse
Keyword(s):  
Hepatitis B ◽  
Cost Benefit Analysis ◽  
Cost Benefit ◽  
Hepatitis B Vaccination ◽  
Benefit Analysis

scholarly journals Hepatitis A virus vaccination strategy and pre-immunization screening of Bangladeshi children

2015 ◽  
Vol 14 (1) ◽  
pp. 65-69
Author(s):  
Salahuddin Mahmud ◽  
ASM Bazlul Karim ◽  
Jahangir Alam ◽  
MM Ziaul Islam ◽  
NK Sarker ◽  
...  
Keyword(s):  
Hepatitis A ◽  
Hepatitis A Virus ◽  
Cost Benefit Analysis ◽  
Medical Science ◽  
Cost Benefit ◽  
Vaccination Strategy ◽  
Mass Vaccination ◽  
Benefit Analysis ◽  
Serum Samples ◽  
Total Cost

Background: HAV infection is endemic in many developing countries like India, Pakistan, Nepal etc. Several seroprevalence studies show high rates of sero-positivity among children by sub-clinical infection. Therefore mass vaccination against HAV has not been recommended in endemic countries. Objective: To determine whether routine hepatitis A vaccination is indicated for all Bangladeshi children & also to know whether pre-vaccination screening is necessary. Materials & Methods: Serum samples from 254 children aged between 1-15 years were tested for antibody (IgM & IgG) against hepatitis A virus (HAV) to determine the seroprevalence of HAV antibody and do a cost-benefit analysis for decision making about vaccination against HAV among the children of Bangladesh. Results: Hepatitis A virus antibody was positive in 141 (55.5%) of 254 children. Age-specific sero-prevalence was 13 (23.2%) of 56 in 1-3 year, 64 (55.2%) of 116 in 3-5 year, 39 (70.9%) of 55 in 5-10 year & 25 (92.6%) of 27 in 10-15 year age group. Cost benefit analysis showed that the total cost of screening followed by vaccination was almost 1.8 times less than the total cost of vaccination of all children without screening. Conclusions: Majority of the children were found sero-positive against HAV around 15 year of age. Therefore mass vaccination against HAV may not be required for Bangladeshi children.DOI: http://dx.doi.org/10.3329/bjms.v14i1.21561 Bangladesh Journal of Medical Science Vol.14(1) 2015 p.65-69

scholarly journals Cost-Benefit Analysis of Hepatitis-B Vaccination: A Computerized Decision Model for Spain

1991 ◽  
Vol 7 (3) ◽  
pp. 379-402 ◽  
Author(s):  
Bengt Jönsson ◽  
Bruno Horisberger ◽  
Miguel Bruguera ◽  
Lukas Matter
Keyword(s):  
Hepatitis B ◽  
Cost Benefit Analysis ◽  
Cost Benefit ◽  
Indirect Costs ◽  
Risk Groups ◽  
Target Population ◽  
Hepatitis B Vaccination ◽  
Benefit Analysis ◽  
Virus Infections ◽  
Duration Of Protection

AbstractThe availability and efficacy of recombinant deoxyribonucleic acid yeast-derived hepatitis-B vaccine, at a price much lower than the previously available plasma-derived hepatitis-B vaccines against hepatitis-B virus infections, motivate a new cost-benefit analysis of hepatitis-B vaccination. Spanish data were used to calculate direct and indirect costs of hepatitis-B infection and the costs and benefits of different vaccination strategies in defined risk groups of the Spanish population. A vaccination program will reduce direct expenditures for hepatitis B if the attack rate in the target population is higher than 4.9%. If indirect costs are included, the threshold for cost saving is reduced to 0.9%. The results are sensitive to the price of the vaccine, the duration of protection, assumptions about consequences for quality of life, and to indirect costs.

scholarly journals Cost-benefit analysis of sheep and goat brucellosis vaccination with Rev.1 in the north of Portugal from 2000 to 2005

2011 ◽  
Vol 63 (1) ◽  
pp. 1-5 ◽  
Author(s):  
A.M Coelho ◽  
M.L Pinto ◽  
A.C Coelho
Keyword(s):  
Cost Benefit Analysis ◽  
Small Ruminants ◽  
Cost Benefit ◽  
Economic Benefits ◽  
Mass Vaccination ◽  
Human Brucellosis ◽  
Benefit Analysis ◽  
The North ◽  
Eradication Campaign ◽  
The Cost

In the North of Portugal, a mass vaccination programme of small ruminants was conducted from 2001 to 2004. A study of cost-benefit was carried out for the 2000/2005 period to ascertain the economic benefits of this strategy. In order to estimate the cost of the zoonosis, the compensation costs paid to farmers for culled animals in the Brucellosis Eradication Campaign, data from vaccine Rev. 1 costs, and costs of people internment due to brucellosis were studied. An increase in the cost was observed from 2000 to 2001 (aproximately US$ 110,000), essentially due to compensation for culled animals, but also from vaccination and human internment costs. However, a progressive decrease was observed from 2001 to 2004 (from more than US$1,200,000 in 2001 to US$180,000 in 2004), roughly US$ 1,020,000 less. As the main conclusion, the annual cost of this zoonosis decreased by an average of almost US$600,000 per year, and a total of more than three million dollars were saved from 2000 to 2005. The results of this study suggest that mass vaccination with Rev. 1 reduced overall costs and was effective in reducing animal and human brucellosis costs

Sign in / Sign up

Export Citation Format

Share Document